SILICON LABORATORIES INC. (SLAB): what the price requires

At today's price, SILICON LABORATORIES INC. (SLAB) is priced for 23.3% operating margins for ~15 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-11 · Source: https://boothcheck.com/report/SLAB

Headline

FieldValue
TickerSLAB
CompanySILICON LABORATORIES INC.
Sector / IndustryTechnology
Current price$218.70/sh
CompositionIndustrial & Commercial 57% / Home & Life 43%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisrevenue-multiple
EV / sales paid8.7x
Steady-state operating margin assumed23.3%
Must persist for14.7y

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 12.7% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.4 years.

Reconcile: at the x-ray's 9.3% required return this reads ~7.7 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history+0.65σ
sustained it ~10 years at this level15%
implied end-window share0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all say richly valued; ONLY the growth-DCF reaches the price. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset6.93x2expensive
Earnings13.40x1expensive
Relative1.76x2expensive
Growth0.89x3justifies

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=8)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$82.112.66xyesFCF base $0.1B, growth 25% (input: historical growth), terminal g 4.0%, WACC 9.2%, 7yr projection
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$124.471.76xyesP/S fallback (negative EPS): Sector P/S 5.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$33.336.56xyesBook value floor: BV/sh $33.33, ROE negative
Two-Stage Excess ReturnAsset$29.997.29xyesBook value with convergence: BV/sh $33.33, ROE converges to ke
Discounted Future Market CapGrowth$334.940.65xyesRev $0.8B, growth 25% (input: historical growth; tapered), Terminal P/S: 7.1x / 8.8x / 10.5x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth$245.490.89xyesMargin ramp: -6% → 25% over 7yr, rev growth 25% (input: historical growth; tapered)
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings$16.3213.40xyesFCF $17.6M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$124.471.76xyesRevenue $0.82B × sector P/S 5.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$438.9m
Interest coverage-60.2x
Share count CAGR (buyback)-4.4%
Burning cashno

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Operating income basisTrailing value
Inversion record (pg-bars)$184.0m
EDGAR quarterly TTM-$55.5m
Divergence431.3%

The inversion header prices the record basis trailing operating income; this strip reads the EDGAR quarterly TTM, and the two diverge by more than 10 percent here. Treat them as different measurement bases, both labeled, neither silently substituted.

Bullet Takeaways

Bull Case

Read Silicon Labs as what it is: a growth-stage semiconductor company whose income statement is mid-recovery, whose revenue line is reaccelerating, and whose end state was just priced by the most disciplined buyer in analog. Texas Instruments signed a definitive agreement on February 4, 2026 to acquire the company for $231.00 per share in cash, an enterprise value near $7.5 billion and a 61% premium to the stock's prior 30-day average. At $218.70 (July 2026), the stock trades below that contract price, so the bull case starts with arithmetic: a signed all-cash deal, shareholder approval already secured on April 30, 2026, and the US antitrust waiting period already expired on April 20, 2026. The holder is paid the gap for bearing time and the remaining regulatory tail.

The operating recovery gives the bet a second engine. First-quarter 2026 revenue rose 20% year over year to $213.5 million, led by Industrial & Commercial at $128 million, up 33%, with bookings accelerating and distributor inventories falling through the quarter. Design-win momentum exceeded both internal targets and the 2025 run rate, which was itself a record year. Design wins are the right lead indicator for this business because of how sticky the sockets are; the 10-K explains that "once a completed design architecture has been implemented and produced in high volumes, our customers are reluctant to significantly alter their designs due to this extensive design-win process" (FY2025 10-K, accession 0001038074-26-000005). Each win embeds Silicon Labs silicon in a product line for years, which is precisely the asset TI is paying for.

The franchise itself is harder to copy than a P&L in a cyclical trough suggests. The company describes "a vast set of trade secrets that allow us to pursue innovative approaches to mixed-signal problems that are difficult for competitors to duplicate" (accession 0001038074-26-000005), and its customer base is unusually diffuse: the "ten largest end customers accounted for 25% of our revenues" with no single customer above 10% (accession 0001038074-26-000005). Add a clean balance sheet ($439 million of net cash, zero gross debt) and a share count that management shrank about 4% a year over the past four years, and the standalone downside case has real support under it. The bull case is a paid wait: collect the spread to $231 if the deal closes, and if it somehow does not, own a debt-free wireless-IoT franchise entering a cyclical upswing with record design-win momentum.

Bear Case

One regulator in Beijing has more leverage over this stock than every customer and competitor combined. The TI acquisition cleared its US antitrust waiting period in April and won shareholder approval, but the deal still needs clearance from China's State Administration for Market Regulation, and as of June 11, 2026 SAMR had not yet formally accepted the filing. China's merger regulator has a documented pattern of slow-walking US semiconductor transactions when trade relations sour, and the companies themselves guide to a close in the first half of 2027, a long runway for policy to shift. The stock's $218.70 price sits about 5% below the $231.00 contract price; that spread is the market's estimate of time plus a real, non-trivial probability that the deal dies in a filing queue.

If the deal breaks, the stock reprices on standalone fundamentals, and those fundamentals do not support anything near the deal price by most static measures. Trailing GAAP operating income is negative on the EDGAR quarterly tally (about negative $56 million; the pricing framework's own record basis reads positive at about $184 million, a divergence driven by how acquisition-era charges and stock compensation land between the two bases). The first quarter still produced a GAAP net loss of $15.9 million even as revenue grew 20%. Free cash flow over the trailing year was thin, and the price stands at roughly 8.7 times revenue, a multiple that assumes the business eventually earns operating margins around 23% and compounds revenue near the fastest pace it can self-fund for well over a decade. Historically only about 15% of comparable fast-growers sustained that pace even ten years.

Competition sets the ceiling on how gracefully those assumptions can land. Silicon Labs sells into wireless connectivity sockets contested by larger rivals; its own filing concedes that some competitors can devote greater "resources to the development, promotion and sale of their products than we can to ours" and that "Competition could decrease our prices, reduce our sales, lower our gross profit and/or decrease our market share" (FY2025 10-K, accession 0001038074-26-000005). The sales channel adds cyclical torque: much of revenue flows through distributors, including Arrow Electronics per the filing (accession 0001038074-26-000005), so a booking surge can reverse as fast as it arrived if end demand disappoints. The bear case is a two-step: SAMR stalls or blocks the deal, and the holder is left with a GAAP-loss-making chip company priced at nearly nine times sales in a cycle that has only begun to turn.

Valuation

Two prices govern this stock, and the distance between them is the whole investment question. The contract price is $231.00 in cash, signed by Texas Instruments in February 2026, shareholder-approved in April, US-cleared in April, and guided to close in the first half of 2027. The market price is $218.70 (July 2026), about 5% below. The gap prices time and Chinese regulatory risk; nothing about the company's quarterly execution moves it much while the deal stands.

Beneath the deal, the standalone reads are stretched, and the pattern across method families says exactly how. Only the forward-growth projections reach today's price; a margin-recovery path (operating margin ramping from today's negative levels toward 25% on sustained growth) lands close to it. Everything static does not come near: peer and sector sales multiples support a price about 40% below today's, the balance-sheet reads sit far beneath at roughly one-seventh of the price, and capitalizing the trailing year's thin free cash flow supports almost nothing. That spread is not a puzzle; it is a description. The price, read against sales at about 8.7 times revenue, embeds an operating margin of roughly 23% that the business has not yet demonstrated and revenue compounding near its self-funding ceiling for around 15 years, a persistence only about 15% of comparable fast-growers have sustained even to year ten. One basis note: trailing operating income is negative on the EDGAR quarterly tally (about negative $56 million) while the framework's record basis carries positive $184 million; the gap reflects different treatment of acquisition-era and non-cash charges, and both describe the same recovering P&L. The revenue foundation, at least, is verifiable in the filing, whose customer base runs diffuse, with the "ten largest end customers accounted for 25% of our revenues" (FY2025 10-K, accession 0001038074-26-000005), and whose channel runs through distributors including Arrow Electronics (accession 0001038074-26-000005).

Solvency is a non-issue and mildly reassuring for the break scenario: $439 million of net cash, zero gross debt, no sustained cash burn, and a share count reduced about 4.4% a year over four years. If the deal closes, none of this matters; holders receive $231.00. If it breaks, the balance sheet funds the recovery, but the price has to renegotiate with fundamentals that currently support far less than the deal does. The decisive number is the filing-acceptance date in Beijing, not anything in the 10-Q.

Catalysts

The deal clock dominates the calendar. Texas Instruments agreed on February 4, 2026 to buy Silicon Labs for $231.00 per share in cash, roughly $7.5 billion of enterprise value and a 61% premium to the preceding 30-day average. The milestones since have all broken clean: HSR filings on March 20, US waiting period expired April 20, and shareholder approval on April 30, 2026 with over 25.8 million votes in favor against roughly 7,500 opposed. The outstanding item is China, where SAMR had not formally accepted the filing as of June 11, 2026. Filing acceptance, any conditions attached, and the pace of review against the guided first-half-2027 close are the catalysts that actually move this stock; each incremental sign of progress narrows the roughly 5% discount to deal terms, and each sign of stall widens it.

The operating tape continues underneath and matters mostly for the break scenario. First-quarter results on May 5, 2026 showed revenue of $213.5 million, up 20% year over year, with Industrial & Commercial up 33% to $128 million and Home & Life up 5% to $86 million; GAAP results stayed in loss at $15.9 million while non-GAAP earnings ran $0.53 per share. Management reported accelerating bookings, falling channel inventories, and design wins running ahead of a record 2025, but suspended forward guidance because of the pending acquisition. Quarterly prints on the usual early-August and early-November cadence will keep scoring the recovery; without guidance, the bookings and inventory commentary are the numbers to read.

For a holder the decision tree is short: deal closes, receive $231.00 in cash; deal stalls into 2027, the discount persists and the recovery quarters accumulate underneath; deal breaks, the stock reprices to standalone fundamentals, with $439 million of net cash and an upturning cycle as the cushion and a near-nine-times-sales multiple as the exposure.

Peer Cohorts (Per Segment, With Filing Citations)

Mixed-signal analog intensive products (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

TI acquisition announcement, February 4, 2026 · SLAB 8-K, April 30, 2026 · HSR filing disclosures, April 2026 · Q1 2026 earnings release, May 5, 2026 · MLex report, June 11, 2026 · TI acquisition announcement and subsequent disclosures, 2026

View the full interactive SLAB report on boothcheck